$NWBO In short, the roadmap is now unmistakably clear: Approval triggers a flood of long‑restricted data, the stock uplists within 2–3 months as the company transforms into a true immunotherapy platform leader, and the endgame becomes a major pharma partnership or a full buyout. NWBO shifts from an overlooked OTC biotech to one of the most strategically valuable assets in oncology! -> Approval -> News avalanche ->Uplisting after 2–3 months -> NWBO becomes a platform icon -> Major BP deal or full buyout Let's go...NWBO
View on X ↗